BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 27989785)

  • 1. Prognostic value of vascular endothelial growth factor (VEGF), VEGF receptor 2, platelet-derived growth factor-β (PDGF-β), and PDGF-β receptor expression in papillary renal cell carcinoma.
    Kim M; Sohn M; Shim M; Choi SK; Park M; Kim E; Go H; Park Y; Cho YM; Ro JY; Jeong IG; Song C; Hong JH; Kim CS; Ahn H
    Hum Pathol; 2017 Mar; 61():78-89. PubMed ID: 27989785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-β phosphorylation, and microvessel density in gastric cancer.
    Suzuki S; Dobashi Y; Hatakeyama Y; Tajiri R; Fujimura T; Heldin CH; Ooi A
    BMC Cancer; 2010 Nov; 10():659. PubMed ID: 21118571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
    Rydén L; Jirström K; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Thorstenson S; Jönsson PE; Landberg G
    J Clin Oncol; 2005 Jul; 23(21):4695-704. PubMed ID: 16034044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and -2 mRNA expression profiles between clear cell and papillary renal cell carcinoma.
    Ljungberg BJ; Jacobsen J; Rudolfsson SH; Lindh G; Grankvist K; Rasmuson T
    BJU Int; 2006 Sep; 98(3):661-7. PubMed ID: 16925769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic role of tumor necrosis, microvessel density, vascular endothelial growth factor and hypoxia inducible factor-1alpha in patients with clear cell renal carcinoma after radical nephrectomy in a long term follow-up.
    Minardi D; Lucarini G; Filosa A; Milanese G; Zizzi A; Di Primio R; Montironi R; Muzzonigro G
    Int J Immunopathol Pharmacol; 2008; 21(2):447-55. PubMed ID: 18547492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinically relevant biomarkers to select patients for targeted inhibitor therapy after resection of hepatocellular carcinoma.
    Patel SH; Kneuertz PJ; Delgado M; Kooby DA; Staley CA; El-Rayes BF; Kauh JS; Sarmiento JM; Hanish S; Cohen C; Farris AB; Maithel SK
    Ann Surg Oncol; 2011 Nov; 18(12):3384-90. PubMed ID: 21590454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphangiogenesis in kidney cancer: expression of VEGF-C, VEGF-D and VEGFR-3 in clear cell and papillary renal cell carcinoma.
    Bierer S; Herrmann E; Köpke T; Neumann J; Eltze E; Hertle L; Wülfing C
    Oncol Rep; 2008 Oct; 20(4):721-5. PubMed ID: 18813809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors in a prospective series of papillary renal cell carcinoma.
    Gontero P; Ceratti G; Guglielmetti S; Andorno A; Terrone C; Bonvini D; Faggiano F; Tizzani A; Frea B; Valente G
    BJU Int; 2008 Sep; 102(6):697-702. PubMed ID: 18489525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib.
    Terakawa T; Miyake H; Kusuda Y; Fujisawa M
    Urol Oncol; 2013 May; 31(4):493-8. PubMed ID: 21478036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coexpression of PDGFR-alpha, PDGFR-beta and VEGF as a prognostic factor in patients with hepatocellular carcinoma.
    Chen L; Shi Y; Jiang CY; Wei LX; Lv YL; Wang YL; Dai GH
    Int J Biol Markers; 2011; 26(2):108-16. PubMed ID: 21574155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic role of Fuhrman grade and vascular endothelial growth factor in pT1a clear cell carcinoma in partial nephrectomy specimens.
    Minardi D; Lucarini G; Mazzucchelli R; Milanese G; Natali D; Galosi AB; Montironi R; Biagini G; Muzzonigro G
    J Urol; 2005 Oct; 174(4 Pt 1):1208-12. PubMed ID: 16145371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type II papillary histology predicts poor outcome in patients with renal cell carcinoma and vena cava thrombus.
    Kim KH; You D; Jeong IG; Kwon TW; Cho YM; Hong JH; Ahn H; Kim CS
    BJU Int; 2012 Dec; 110(11 Pt B):E673-8. PubMed ID: 22973869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bronchial washing levels of vascular endothelial growth factor receptor-2 (VEGFR2) correlate with overall survival in NSCLC patients.
    Charpidou A; Gkiozos I; Konstantinou M; Eleftheraki A; Demertzis P; Harrington K; Polyzos A; Syrigos KN
    Cancer Lett; 2011 May; 304(2):144-53. PubMed ID: 21396771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of insulin- like growth factor-I receptor expression in renal cell carcinoma.
    Sichani MM; Yazdi FS; Moghaddam NA; Chehrei A; Kabiri M; Naeimi A; Taheri D
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):69-74. PubMed ID: 20061696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
    Dosquet C; Coudert MC; Lepage E; Cabane J; Richard F
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis.
    Bonnesen B; Pappot H; Holmstav J; Skov BG
    Lung Cancer; 2009 Dec; 66(3):314-8. PubMed ID: 19324448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of peri-operative peripheral and renal venous levels of pro- and anti-angiogenic factors and their relevance in patients with renal cell carcinoma.
    Klatte T; Böhm M; Nelius T; Filleur S; Reiher F; Allhoff EP
    BJU Int; 2007 Jul; 100(1):209-14. PubMed ID: 17428240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients.
    Mele T; Generali D; Fox S; Brizzi MP; Bersiga A; Milani M; Allevi G; Bonardi S; Aguggini S; Volante M; Dogliotti L; Bottini A; Harris A; Berruti A
    Breast Cancer Res Treat; 2010 Oct; 123(3):795-804. PubMed ID: 20680681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma.
    Klatte T; Pantuck AJ; Said JW; Seligson DB; Rao NP; LaRochelle JC; Shuch B; Zisman A; Kabbinavar FF; Belldegrun AS
    Clin Cancer Res; 2009 Feb; 15(4):1162-9. PubMed ID: 19228721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of platelet-derived growth factors in non-small cell lung cancer tumor and stromal cells.
    Donnem T; Al-Saad S; Al-Shibli K; Andersen S; Busund LT; Bremnes RM
    J Thorac Oncol; 2008 Sep; 3(9):963-70. PubMed ID: 18758297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.